title: Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
abstract: OBJECTIVE
  Salivary duct carcinoma is a rare and aggressive tumor of the salivary glands. The objectives of this study were to investigate the clinicopathological features of salivary duct carcinoma and to determine whether androgen deprivation therapy should be recommended.
  
  
  METHODS
  The clinical records of seven patients diagnosed with salivary duct carcinoma between 2002 and 2012 were retrospectively assessed. Tumor specimens were examined for overexpression of human epidermal growth factor receptor 2 (HER2) and androgen receptor by immunohistochemistry. A case of androgen receptor-positive salivary duct carcinoma who received androgen deprivation therapy is presented.
  
  
  RESULTS
  Of the seven patients, 43% had recurrences and metastases, and the 5-year survival rate was 68.6%. All patients were androgen receptor-positive, and 71% were HER2-positive. One patient, a 66-year-old man with androgen receptor-positive salivary duct carcinoma, received oral bicalutimide for 14 months and practically all lung metastases disappeared.
  
  
  CONCLUSIONS
  Androgen receptor is often overexpressed in salivary duct carcinoma. Androgen deprivation therapy is safe and should be considered for patients with androgen receptor-positive salivary duct carcinoma.
authors.affiliation: Department of Otolaryngology, National Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo, Japan. Electronic address: nobukoy@a2.keio.jp.
authors.forename: Nobuko
authors.initials: N
authors.lastname: Yamamoto
authors.affiliation: Department of Otolaryngology, National Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo, Japan.
authors.forename: Shujiro
authors.initials: S
authors.lastname: Minami
authors.affiliation: National Institute of Sensory Organs, National Tokyo Medical Center, 2-5-1, Higashigaoka, Meguro-ku, Tokyo, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Fujii
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism*; D011944:Receptors, Androgen / Q000378:metabolism*; D018987:Salivary Ducts; D012468:Salivary Gland Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D014105:Tosyl Compounds / Q000627:therapeutic use*
chemical_list: D000726:Androgen Antagonists; D000813:Anilides; D009570:Nitriles; D018719:Erb-b2 Receptor Tyrosine Kinases; D011944:Receptors, Androgen; D014105:Tosyl Compounds; C053541:bicalutamide; C508053:ERBB2 protein, human